Tower Research Capital LLC TRC Grows Holdings in Arcellx, Inc. (NASDAQ:ACLX)

Tower Research Capital LLC TRC grew its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 1,081.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,984 shares of the company's stock after purchasing an additional 7,308 shares during the quarter. Tower Research Capital LLC TRC's holdings in Arcellx were worth $612,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ACLX. Xponance Inc. lifted its position in Arcellx by 8.6% during the fourth quarter. Xponance Inc. now owns 3,088 shares of the company's stock worth $237,000 after buying an additional 244 shares during the period. KBC Group NV increased its stake in shares of Arcellx by 37.3% during the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after acquiring an additional 377 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Arcellx by 0.8% during the 4th quarter. Swiss National Bank now owns 63,400 shares of the company's stock worth $4,862,000 after acquiring an additional 500 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Arcellx in the fourth quarter worth approximately $41,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Arcellx by 9.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock valued at $754,000 after purchasing an additional 858 shares during the period. Institutional investors and hedge funds own 96.03% of the company's stock.

Insider Transactions at Arcellx

In related news, Director Kavita Patel sold 1,500 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total transaction of $96,855.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rami Elghandour sold 38,300 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total value of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. This represents a 20.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,955 shares of company stock worth $3,504,758. 6.24% of the stock is currently owned by company insiders.

Arcellx Price Performance

NASDAQ:ACLX traded up $0.02 during trading hours on Friday, reaching $65.55. 305,387 shares of the company were exchanged, compared to its average volume of 554,266. The firm has a market cap of $3.61 billion, a price-to-earnings ratio of -92.32 and a beta of 0.33. The stock has a 50 day simple moving average of $64.90 and a 200 day simple moving average of $73.92. Arcellx, Inc. has a 52-week low of $47.88 and a 52-week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The firm had revenue of $15.27 million during the quarter, compared to analyst estimates of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. On average, analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).